Adverse event profile with once-monthly oral ibandronate: The MOBILE study long-term extension.

被引：0
|
作者：
Silverman, S.
Emkey, R.
Reginster, J. Y.
Lorenc, R.
Hughes, C.
Kendler, D.
机构：
[1] Cedars Sinai Med Ctr, Los Angeles, CA 90048 USA
[2] Radiant Res, Wyomissing, PA USA
[3] Univ Liege, B-4000 Liege, Belgium
[4] Childrens Mem Inst, Warsaw, Poland
[5] F Hoffmann La Roche Ltd, Basel, Switzerland
[6] Univ British Columbia, Osteoporosis Res Ctr, Vancouver, BC V5Z 1M9, Canada
来源：
JOURNAL OF BONE AND MINERAL RESEARCH | 2006年 / 21卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：S418 / S418
页数：1
相关论文
共 50 条
  • [31] Once-monthly oral ibandronate (Boniva) dosing is highly efficacious in postmenopausal osteoporosis: 2-year results from MOBILE
    Silverman, S
    Greenwald, M
    Hawker, G
    Hughes, C
    Mairon, N
    Bonvoisin, B
    Reginster, JY
    ARTHRITIS AND RHEUMATISM, 2005, 52 (09): : S735 - S736
  • [32] Long-term adalimumab adverse event profile
    Reactions Weekly, 2017, 1681 (1) : 9 - 9
  • [33] Long-term safety and tolerability of aripiprazole once-monthly in maintenance treatment of patients with schizophrenia
    Fleischhacker, W. Wolfgang
    Sanchez, Raymond
    Johnson, Brian
    Jin, Na
    Forbes, Robert A.
    McQuade, Robert
    Baker, Ross A.
    Carson, William
    Kane, John M.
    INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, 2013, 28 (04) : 171 - 176
  • [34] Sandostatin LAR Depot - Once-monthly IM formulation for long-term maintenance therapy
    不详
    FORMULARY, 1999, 34 (03) : 194 - 194
  • [35] Efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: 2 year results from the MOBILE study (vol 65, pg 654, 2006)
    Reginster, J-Y
    Adami, S.
    Lakatos, P.
    Greenwald, M.
    Stepan, J. J.
    Silverman, S. L.
    ANNALS OF THE RHEUMATIC DISEASES, 2008, 67 (02) : 280 - 280
  • [36] Influence of baseline patient characteristics on response to once-monthly and daily oral ibandronate therapy: 2-year findings from mobile
    Reginster, J. Y.
    Hawker, G.
    Bolognese, M.
    Coutant, K.
    Hughes, C.
    Sedarati, F.
    Stone, M.
    ANNALS OF THE RHEUMATIC DISEASES, 2006, 65 : 426 - 426
  • [37] Once-monthly dosing of oral ibandronate is at least as effective as daily dosing in postmenopausal osteoporosis: 1-year results from mobile
    Reginster, JY
    Zikan, V
    Lorenc, R
    Hughes, C
    Mairon, N
    Bonvoisin, B
    Stakkestad, JA
    BONE, 2005, 36 : S416 - S416
  • [38] Once-monthly and daily oral ibandronate are similarly well tolerated in women with postmenopausal osteoporosis: 2-year results from mobile
    Luckey, M.
    Stepan, J.
    Kendler, D. L.
    Feldman, D.
    Lipschitz, S.
    Leigh, C.
    Burdeska, A.
    Hiltbrunner, V
    Morales-Torres, J.
    OSTEOPOROSIS INTERNATIONAL, 2006, 17 : S234 - S234
  • [39] Large proportions of women with postmenopausal osteoporosis respond to once-monthly oral ibandronate: 2-year results from MOBILE.
    Recker, RR
    Luckey, M
    Stakkestad, JA
    Civitelli, R
    Hughes, C
    Mairon, N
    Bonvoisin, B
    Cooper, C
    JOURNAL OF BONE AND MINERAL RESEARCH, 2005, 20 (09) : S395 - S395
  • [40] Once-monthly oral ibandronate compared with weekly oral alendronate in postmenopausal osteoporosis: results from the head-to-head MOTION study
    Miller, Paul D.
    Epstein, Sol
    Sedarati, Farhad
    Reginster, Jean-Yves
    CURRENT MEDICAL RESEARCH AND OPINION, 2008, 24 (01) : 207 - 213
12345